Q2 2013 Holdings
Filed 2013-08-14 | 23 holdings | $25.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc.(ALNY) | COM | 02043Q107 | $14.1M | 454,800 | 55.5% |
| Biomarin Pharmaceutical Inc(BMRN) | COM | 09061G101 | $9.9M | 178,028 | 39.1% |
| Celgene Corporation(CELG) | COM | 151020104 | $251.5K | 2,150,186 | 1.0% |
| Isis Pharmaceuticals, Inc. | COM | 464330109 | $208.8K | 7,769,172 | 0.8% |
| Gilead Sciences, Inc.(GILD) | COM | 375558103 | $189.7K | 3,700,000 | 0.7% |
| Incyte Corporation(INCY) | COM | 45337C102 | $117.9K | 5,357,149 | 0.5% |
| Vertex Pharmaceuticals Incorporated(VRTX) | COM | 92532F100 | $112.4K | 1,404,445 | 0.4% |
| Alexion Pharmaceuticals, Inc.(ALXN) | COM | 015351109 | $71.8K | 778,126 | 0.3% |
| Medivation, Inc. | COM | 58501N101 | $71.3K | 1,449,706 | 0.3% |
| Ariad Pharmaceuticals, Inc | COM | 04033A100 | $54.5K | 3,115,371 | 0.2% |
| Immunogen, Inc.(IMGNEUR) | COM | 45253H101 | $54.1K | 3,262,094 | 0.2% |
| Onyx Pharmaceuticals, Inc. | COM | 683399109 | $47.4K | 546,500 | 0.2% |
| Halozyme Therapeutics, Inc.(HALO) | COM | 40637H109 | $44.9K | 5,646,519 | 0.2% |
| Theravance, Inc. | COM | 88338T104 | $34.2K | 888,244 | 0.1% |
| Endocyte, Inc. | COM | 29269A102 | $30.7K | 2,339,345 | 0.1% |
| Optimer Pharmaceuticals, Inc. | COM | 68401H104 | $20.9K | 1,446,700 | 0.1% |
| Infinity Pharmaceuticals, Inc.(INFIQ) | COM | 45665G303 | $17.6K | 1,089,828 | 0.1% |
| Achillion Pharmaceuticals, Inc(ACHNEUR) | COM | 00448Q201 | $13.7K | 1,679,340 | 0.1% |
| The Medicines Company | COM | 584688105 | $9.3K | 302,993 | 0.0% |
| Idenix Pharmaceuticals, Inc. | COM | 45166R204 | $4.5K | 1,250,000 | 0.0% |
| Dendreon Corporation | COM | 24823Q107 | $4.2K | 1,014,800 | 0.0% |
| Trius Therapeutics, Inc. | COM | 89685K100 | $2.3K | 280,000 | 0.0% |
| Synageva BioPharma Corp. | COM | 87159A103 | $2.2K | 53,549 | 0.0% |